BrainStorm Cell Therapeutics Inc. reported its financial results for the first quarter ended March 31, 2025. The company, focused on developing adult stem cell therapeutics for neurodegenerative diseases, recorded a net loss of approximately $2.9 million for the quarter, a decrease from the net loss of approximately $3.4 million in the same period the previous year. Research and development expenditures increased to $1.3 million, compared to $1.0 million for the quarter ended March 31, 2024. General and administrative expenses also rose to approximately $1.8 million from approximately $1.5 million in the corresponding quarter of the prior year. In addition to financial results, BrainStorm provided a corporate update on its NurOwn® development program. The company announced an IND amendment submission for NurOwn to the U.S. Food and Drug Administration, paving the way for the initiation of a Phase 3b clinical trial. This trial, designed in collaboration with the FDA under a Special Protocol Assessment, aims to confirm the product's efficacy in early-stage ALS patients. Furthermore, BrainStorm's leadership presented biomarker insights at the 2025 ALS Drug Development Summit, emphasizing the relationship between cerebrospinal fluid biomarker pathways and clinical outcomes in ALS treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.